Ki-67 Labeling Index in Pulmonary Carcinoid Tumors

Ki-67 labeling index is incorporated into the 3-tiered grading system for neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tract (grade 1 tumors have Ki-67 <3% by hot spot method; grade 2 tumors have Ki-67 between 3% and 20%; grade 3 neoplasms have Ki-67 >20%).8 Although...

Full description

Saved in:
Bibliographic Details
Published inArchives of pathology & laboratory medicine (1976) Vol. 144; no. 8; pp. 982 - 990
Main Authors Boland, Jennifer M, Kroneman, Trynda N, Jenkins, Sarah M, Terra, Simone B S P, Xie, Hao, Molina, Julian, Mounajjed, Taofic, Roden, Anja C
Format Journal Article
LanguageEnglish
Published Northfield College of American Pathologists 01.08.2020
Subjects
Automation
Biopsy
Histology
Image processing
Labeling
Lung cancer
Lymphatic system
Metastasis
Methods
Neoplasia
Neuroendocrine tumors
Paraffin
Quality control
Stains & staining
Tumors
Online AccessGet full text

Cover

More Information
Summary:Ki-67 labeling index is incorporated into the 3-tiered grading system for neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tract (grade 1 tumors have Ki-67 <3% by hot spot method; grade 2 tumors have Ki-67 between 3% and 20%; grade 3 neoplasms have Ki-67 >20%).8 Although Ki-67 is not currently used in the WHO grading scheme for pulmonary carcinoids, many studies have shown that ACTs have increased Ki-67, and that increased Ki-67 is generally associated with poorer prognosis.2,9-24 However, the use of Ki-67 labeling index in the evaluation of pulmonary carcinoid tumors is controversial and not standardized, because there are conflicting data regarding the added value to the current WHO system. Ki-67 immunostaining (clone MIB1, Dako, Carpintería, California) was performed on formalin-fixed, paraffin-embedded tissue sections from both biopsy/cell block and resection specimens (1 representative whole tissue section was stained for resection specimens to include any areas of increased mitotic activity, if applicable). Ki-67 labeling index was determined via digital image analysis by an experienced technologist, using both hot spot and tumor tracing methods. Manual assessment of Ki-67 was performed in 10% of cases by a pathologist as a quality control measure, which included verification of placement of hot spot boxes, confirmation of excluded nontumor areas/cells, and counting of at least 5 high-power fields for a manual estimate of Ki-67 both in hot spot areas and at random; no discrepancies were identified from the automated reads.
ISSN:0003-9985
1543-2165
DOI:10.5858/arpa.2019-0374-OA